JP2016116527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016116527A5 JP2016116527A5 JP2016023490A JP2016023490A JP2016116527A5 JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5 JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016023490 A JP2016023490 A JP 2016023490A JP 2016116527 A5 JP2016116527 A5 JP 2016116527A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- treatment
- mammalian
- fibrosis
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36469810P | 2010-07-15 | 2010-07-15 | |
| US61/364,698 | 2010-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519849A Division JP5886283B2 (ja) | 2010-07-15 | 2011-07-15 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016116527A JP2016116527A (ja) | 2016-06-30 |
| JP2016116527A5 true JP2016116527A5 (enExample) | 2016-09-08 |
| JP6223483B2 JP6223483B2 (ja) | 2017-11-01 |
Family
ID=44630044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519849A Expired - Fee Related JP5886283B2 (ja) | 2010-07-15 | 2011-07-15 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
| JP2016023490A Expired - Fee Related JP6223483B2 (ja) | 2010-07-15 | 2016-02-10 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519849A Expired - Fee Related JP5886283B2 (ja) | 2010-07-15 | 2011-07-15 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8940300B2 (enExample) |
| EP (2) | EP3345925A3 (enExample) |
| JP (2) | JP5886283B2 (enExample) |
| KR (1) | KR101695056B1 (enExample) |
| CN (2) | CN103153331B (enExample) |
| AU (1) | AU2011279044B2 (enExample) |
| BR (1) | BR112013001062A2 (enExample) |
| CA (1) | CA2805112A1 (enExample) |
| DK (1) | DK2593128T3 (enExample) |
| ES (1) | ES2665317T3 (enExample) |
| HR (1) | HRP20180563T1 (enExample) |
| HU (1) | HUE038000T2 (enExample) |
| IL (2) | IL224186A (enExample) |
| LT (1) | LT2593128T (enExample) |
| MX (1) | MX343376B (enExample) |
| NO (1) | NO2593128T3 (enExample) |
| PT (1) | PT2593128T (enExample) |
| RS (1) | RS57215B1 (enExample) |
| SG (1) | SG187097A1 (enExample) |
| SI (1) | SI2593128T1 (enExample) |
| WO (1) | WO2012009631A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2711394A1 (en) | 2008-01-11 | 2009-07-16 | Synovex Corporation | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
| EP3345925A3 (en) | 2010-07-15 | 2018-09-26 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
| EP2771031B1 (en) | 2011-10-28 | 2018-04-18 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| EP2807188B1 (en) | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| CN104203280A (zh) * | 2012-03-27 | 2014-12-10 | 诺华股份有限公司 | 纤维化的治疗 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| EP2970489A2 (en) * | 2013-03-15 | 2016-01-20 | AbbVie Biotechnology Ltd | Anti-cd25 antibodies and their uses |
| AU2014233478A1 (en) * | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US11097005B2 (en) * | 2014-12-15 | 2021-08-24 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity |
| WO2017120557A1 (en) * | 2016-01-09 | 2017-07-13 | Arbele Limited | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment |
| PL3830119T3 (pl) * | 2018-08-01 | 2026-05-25 | Imcheck Therapeutics | Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych |
| CN113072633B (zh) * | 2021-04-21 | 2022-11-15 | 湖北医药学院 | Cdh11截短型变体及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| WO1987001130A1 (en) | 1985-08-15 | 1987-02-26 | Stauffer Chemical Company | Tryptophan producing microorganism |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| EP0464533B1 (de) | 1990-06-28 | 1998-07-29 | Hoechst Aktiengesellschaft | Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| JP3560252B2 (ja) * | 1992-08-28 | 2004-09-02 | アベンティス ファーマ株式会社 | 骨関連カドヘリン様タンパク質およびその製造法 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| US6638911B1 (en) | 1998-05-05 | 2003-10-28 | Adherex Technologies Inc. | Compounds and methods for modulating desmosomal cadherin-mediated functions |
| EP1075494A2 (en) | 1998-05-05 | 2001-02-14 | Adherex Technologies, Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| US7481999B2 (en) | 1998-05-05 | 2009-01-27 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin-mediated function |
| US6472367B1 (en) | 1998-05-05 | 2002-10-29 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin mediated cell adhesion |
| US6787136B1 (en) | 1999-09-03 | 2004-09-07 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| CA2384115C (en) | 1999-09-03 | 2016-08-02 | Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| US7476509B2 (en) | 2002-11-14 | 2009-01-13 | Adherex Technologies Inc. | Compounds and methods for modulating functions of nonclassical cadherins |
| WO2006089397A1 (en) | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Methods for treating arthritis using triheterocyclic compounds |
| CA2711394A1 (en) * | 2008-01-11 | 2009-07-16 | Synovex Corporation | Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders |
| JP2011514318A (ja) * | 2008-02-11 | 2011-05-06 | ノバルティス アーゲー | カドヘリン１１（ｃｄｈ１１）アンタゴニストの使用方法 |
| EP3345925A3 (en) | 2010-07-15 | 2018-09-26 | Adheron Therapeutics, Inc. | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
-
2011
- 2011-07-15 EP EP17203400.1A patent/EP3345925A3/en not_active Withdrawn
- 2011-07-15 US US13/810,018 patent/US8940300B2/en active Active
- 2011-07-15 CN CN201180042808.0A patent/CN103153331B/zh not_active Expired - Fee Related
- 2011-07-15 SI SI201131461T patent/SI2593128T1/en unknown
- 2011-07-15 PT PT117417170T patent/PT2593128T/pt unknown
- 2011-07-15 ES ES11741717.0T patent/ES2665317T3/es active Active
- 2011-07-15 DK DK11741717.0T patent/DK2593128T3/en active
- 2011-07-15 MX MX2013000434A patent/MX343376B/es active IP Right Grant
- 2011-07-15 SG SG2013003454A patent/SG187097A1/en unknown
- 2011-07-15 WO PCT/US2011/044172 patent/WO2012009631A1/en not_active Ceased
- 2011-07-15 HU HUE11741717A patent/HUE038000T2/hu unknown
- 2011-07-15 RS RS20180419A patent/RS57215B1/sr unknown
- 2011-07-15 AU AU2011279044A patent/AU2011279044B2/en not_active Ceased
- 2011-07-15 HR HRP20180563TT patent/HRP20180563T1/hr unknown
- 2011-07-15 LT LTEP11741717.0T patent/LT2593128T/lt unknown
- 2011-07-15 CN CN201710140463.1A patent/CN107090039A/zh active Pending
- 2011-07-15 NO NO11741717A patent/NO2593128T3/no unknown
- 2011-07-15 JP JP2013519849A patent/JP5886283B2/ja not_active Expired - Fee Related
- 2011-07-15 KR KR1020137003804A patent/KR101695056B1/ko not_active Expired - Fee Related
- 2011-07-15 CA CA2805112A patent/CA2805112A1/en not_active Abandoned
- 2011-07-15 EP EP11741717.0A patent/EP2593128B1/en active Active
- 2011-07-15 BR BR112013001062A patent/BR112013001062A2/pt not_active Application Discontinuation
-
2013
- 2013-01-13 IL IL224186A patent/IL224186A/en active IP Right Grant
-
2015
- 2015-01-26 US US14/605,543 patent/US20150132305A1/en not_active Abandoned
-
2016
- 2016-01-26 IL IL243775A patent/IL243775A0/en unknown
- 2016-02-10 JP JP2016023490A patent/JP6223483B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| JP2018127467A5 (enExample) | ||
| JP2018504907A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| JP2011157378A5 (enExample) | ||
| MX2018015584A (es) | Anticuerpos anti-pd-l1 y usos de los mismos. | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| JP2016502515A5 (enExample) | ||
| JP2014534239A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2019526543A5 (enExample) | ||
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| JP2021504430A5 (enExample) | ||
| JP2016515522A5 (enExample) | ||
| MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
| JP2014503189A5 (enExample) | ||
| MX395257B (es) | Anticuerpos para cd40. | |
| JP2016185981A5 (enExample) | ||
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| JP2014237714A5 (enExample) | ||
| MX2015011772A (es) | Anticuerpos anti-hepcidina y usos de los mismos. | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE |